Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $616M | $134M | $447M | $-25M | 69.0% | 87.3% | 1812.4% |
| 2024 | $329M | $50M | $23M | $-41M | 10.5% | 40.8% | 84.5% |
| 2023 | $234M | $26M | $13M | $-31M | 7.9% | 8290.0% | -105.7% |
| 2022 | $3M | $-213M | $-224M | $-176M | -382.0% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 616.29 |
| Operating Revenue | 616.29 |
| Cost Of Revenue | 100.71 |
| Gross Profit | 515.57 |
| Operating Expense | 392.25 |
| Research And Development | 160.22 |
| Selling General And Administration | 232.03 |
| Total Expenses | 492.96 |
| Operating Income | 123.32 |
| Total Operating Income As Reported | 123.32 |
| EBITDA | 134.36 |
| Normalized EBITDA | 134.36 |
| EBIT | 134.12 |
| Interest Expense | 26.73 |
| Net Interest Income | -26.73 |
| Other Non Operating Income Expenses | 10.79 |
| Other Income Expense | 10.79 |
| Interest Expense Non Operating | 26.73 |
| Net Non Operating Interest Income Expense | -26.73 |
| Pretax Income | 107.39 |
| Tax Provision | -339.79 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | 447.18 |
| Net Income From Continuing And Discontinued Operation | 447.18 |
| Net Income From Continuing Operation Net Minority Interest | 447.18 |
| Net Income | 447.18 |
| Net Income Common Stockholders | 447.18 |
| Net Income Including Noncontrolling Interests | 447.18 |
| Normalized Income | 447.18 |
| Diluted NI Availto Com Stockholders | 447.18 |
| Basic Average Shares | 144.32 |
| Diluted Average Shares | 161.41 |
| Reconciled Depreciation | 0.24 |
| Reconciled Cost Of Revenue | 100.71 |
| General And Administrative Expense | 232.03 |
| Other Gand A | 183.98 |
| Salaries And Wages | 48.05 |
| Selling And Marketing Expense | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| TG Therapeutics, Inc.this co. | TGTX | $6.2B | 13.88 | 9.58 | 69.0% | 47.51 |
| Alkermes plc | ALKS | $7.2B | 29.92 | 3.97 | 13.3% | 20.89 |
| Glaukos Corporation | GKOS | $7.1B | -38.08 | 10.89 | -28.6% | -49.02 |
| Protagonist Therapeutics, Inc. | PTGX | $6.6B | -50.79 | 10.75 | -21.2% | -41.39 |
| PTC Therapeutics, Inc. | PTCT | $5.9B |
| - |
| - |
| - |
| - |
| - |
| - |
| 8.58 |
| - |
| -332.5% |
| 7.46 |
| Teleflex Incorporated | TFX | $5.8B | -6.46 | 1.87 | -29.0% | 27.09 |
| Apellis Pharmaceuticals, Inc. | APLS | $5.3B | 234.62 | 14.19 | 6.0% | 75.16 |
| Ligand Pharmaceuticals Incorporated | LGND | $4.7B | 37.99 | 4.65 | 12.2% | 25.35 |
| Indivior Pharmaceuticals, Inc. | INDV | $4.4B | 21.08 | -44.71 | -212.1% | 15.07 |
| Peer Median | - | 14.83 | 4.65 | -24.9% | 17.98 | |